Immune cells for EBV-related diseases after transplant
Part of Infections clinical trials.
This trial tests a new treatment using specially prepared immune cells (called T cells) that fight the Epstein-Barr virus (EBV). It is for people who have EBV-related conditions, especially after a stem cell or organ transplant, and aims to help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an EBV-related disease, such as certain lymphomas or complications after a transplant.
- You are planning to have or have had a stem cell or organ transplant.
- You are not pregnant (if you are a woman who can have children).
- You have not had a severe reaction to a substance called DMSO.
- You do not have severe graft-versus-host disease (a condition where donor cells attack your body).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
Hear when a new EBV Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.